VIDEO: Exploring possibility of off-drug remission in atopic dermatitis

ByRaj Chovatiya, MD, PhD

ByRebecca L. Forand

Fact checked byKristen Dowd

CLEVELAND — For patients with atopic dermatitis, today’s systemic therapies can lead to long-standing on-drug relief, but long-term, off-drug remission remains a goal that has yet to be reached, according to Raj Chovatiya, MD, PhD.

Chovatiya, clinical associate professor at Chicago Medical School at Rosalind Franklin University and founder and director of the Center for Medical Dermatology and Immunology Research, discussed the possibility of remission in AD at the Medical Dermatology Therapy Update III meeting.

While research has shown many of the current therapies lead to lasting results, it is unclear if it is true remission or just mechanism of action, he said. But ongoing studies are looking at new drugs that could be a way to have long-lasting off-drug effects as well.

Published by:

Sources/Disclosures

Collapse

Source:

Chovatiya R. Update in the treatment of atopic dermatitis: Exploring the concept of remission with systemic therapy. Presented at: Medical Dermatology Therapy Update III; May 29-31, 2024; Cleveland.

Disclosures: Chovatiya reports being an advisor, consultant, speaker and/or investigator for AbbVie, AnaptysBio, Amgen, Apogee Therapeutics, Arcutis, Argenx, Aslan, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Kera Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Galderma, Genentech, GSK, Incyte, LEO Pharma, L’Oreal, Nektar Therapeutics, Novartis, Opsidio, Pfizer, RAPT Therapeutics, Regeneron, Sanofi, Sitryx and UCB.

Read more

VIDEO: Exploring possibility of off-drug remission in atopic dermatitis

Related Content